HCA Healthcare Inc (NYSE:HCA) – Analysts at Piper Sandler reduced their Q2 2020 EPS estimates for HCA Healthcare in a research report issued to clients and investors on Wednesday, July 8th. Piper Sandler analyst S. James now anticipates that the company will post earnings per share of $0.32 for the quarter, down from their prior forecast of $0.90. Piper Sandler also issued estimates for HCA Healthcare’s Q3 2020 earnings at $1.62 EPS, Q4 2020 earnings at $2.97 EPS, Q2 2021 earnings at $2.59 EPS, Q3 2021 earnings at $2.65 EPS, Q4 2021 earnings at $3.10 EPS and FY2021 earnings at $11.22 EPS.

HCA Healthcare (NYSE:HCA) last released its earnings results on Tuesday, April 21st. The company reported $2.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.64 by ($0.31). The firm had revenue of $12.86 billion for the quarter, compared to analyst estimates of $13.12 billion. HCA Healthcare had a negative return on equity of 304.76% and a net margin of 5.90%. The firm’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.97 EPS.

A number of other research analysts have also commented on HCA. TheStreet lowered shares of HCA Healthcare from a “b-” rating to a “c+” rating in a research report on Monday, March 30th. Credit Suisse Group reaffirmed a “buy” rating and set a $173.00 price objective on shares of HCA Healthcare in a research report on Thursday, March 19th. Oppenheimer cut their price objective on shares of HCA Healthcare from $160.00 to $135.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Zacks Investment Research lowered shares of HCA Healthcare from a “hold” rating to a “sell” rating and set a $103.00 price objective for the company. in a research report on Tuesday, June 23rd. Finally, Citigroup cut their price objective on shares of HCA Healthcare from $168.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have given a buy rating to the company. HCA Healthcare currently has an average rating of “Buy” and a consensus target price of $145.00.

HCA Healthcare stock opened at $96.83 on Monday. The firm has a market cap of $32.25 billion, a price-to-earnings ratio of 11.02, a P/E/G ratio of 2.14 and a beta of 1.30. HCA Healthcare has a fifty-two week low of $58.38 and a fifty-two week high of $151.97. The firm has a fifty day moving average price of $102.19 and a two-hundred day moving average price of $117.35.

In other HCA Healthcare news, insider Jon M. Foster sold 24,220 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $100.19, for a total transaction of $2,426,601.80. Following the sale, the insider now directly owns 49,212 shares of the company’s stock, valued at $4,930,550.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of HCA. Cutler Group LP grew its stake in HCA Healthcare by 102.1% during the first quarter. Cutler Group LP now owns 300 shares of the company’s stock worth $26,000 after buying an additional 14,400 shares during the last quarter. City Holding Co. lifted its position in shares of HCA Healthcare by 903.2% during the first quarter. City Holding Co. now owns 311 shares of the company’s stock worth $28,000 after purchasing an additional 280 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of HCA Healthcare by 57.8% during the first quarter. Bessemer Group Inc. now owns 363 shares of the company’s stock worth $33,000 after purchasing an additional 133 shares in the last quarter. Solstein Capital LLC acquired a new position in shares of HCA Healthcare during the first quarter worth approximately $36,000. Finally, Penserra Capital Management LLC lifted its position in shares of HCA Healthcare by 50.8% during the fourth quarter. Penserra Capital Management LLC now owns 294 shares of the company’s stock worth $41,000 after purchasing an additional 99 shares in the last quarter. 68.68% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Further Reading: Guidelines for Successful Channel Trading

Earnings History and Estimates for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.